Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus
Vaccine was safe and elicited a potent immune response Cytomegalovirus (CMV) infection is the leading cause of birth defects in the developed world, occurring in 1 – 2.5 % of all newborns and conferring risk of deafness and impaired intellectual …